Advertisement
UK markets close in 3 hours 34 minutes

  • FTSE 100

    8,088.60
    +43.79 (+0.54%)
     

  • FTSE 250

    19,806.33
    +6.61 (+0.03%)
     

  • AIM

    754.93
    +0.06 (+0.01%)
     

  • GBP/EUR

    1.1632
    +0.0004 (+0.04%)
     

  • GBP/USD

    1.2432
    -0.0021 (-0.17%)
     

  • Bitcoin GBP

    53,494.14
    +347.70 (+0.65%)
     

  • CMC Crypto 200

    1,438.06
    +13.96 (+0.98%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    83.03
    -0.33 (-0.40%)
     

  • GOLD FUTURES

    2,329.60
    -12.50 (-0.53%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,197.83
    +60.18 (+0.33%)
     

  • CAC 40

    8,138.06
    +32.28 (+0.40%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Merck KGaA (MKGAF) Q3 Earnings Down Y/Y, Sales Flat

Zacks Equity Research
Updated

Merck KGaA MKGAF is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.

The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.

The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.

At its 2016 Capital Market Day, the company provided an update on its objectives up to 2018.  Beginning 2017, the company aims to gain approval of one medicine or new indication every year.

ADVERTISEMENT

We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: The company’s third-quarter 2017 earnings per American Depositary Receipt (ADR) came in at $1.77, compared to the year-ago figure of $1.90.

Revenue: The company posted revenues of $4.35 billion in the reported quarter. The Healthcare and Life Science segment drove the company’s organic growth.

Key Stats: The company’s multiple sclerosis therapy, Mavenclad, received recommendation from NICE for approval in UK. Bavencio received approval in the EU and Japan for treating metastatic Merkel cell carcinoma in late September. Moreover, Merck completed the divestment of its Biosimilars business to Fresenius as a part of its strategy to become a leading science and technology company.

Guidance Reiterated: For 2017, the company maintained its net sales forecast in the range of €15.3 billion – €15.7 billion. The company expects net sales to be at the lower end of the expected range due to appreciating Euro. The company reiterated its earnings per share forecast in the range of €6.15 - €6.50.

Merck KGaA Price and EPS Surprise

 

Merck KGaA Price and EPS Surprise | Merck KGaA Quote

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.